Carsten Reinhardt, M.D. Ph.D.

Chief Development Officer

Managing Director Immatics Biotechnologies GmbH

As Managing Director and Chief Development Officer Carsten Reinhardt leads Immatics’ product development strategy. He also holds overall responsibility for the TCR Bispecifics platform and pipeline and oversees the Immunology and Translational Development functions at Immatics.

He joined Immatics in October 2009 from Micromet Inc. (Bethesda, MD), where he was Chief Medical Officer and a member of the management board. Previously, as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland), Carsten Reinhardt had global responsibility for the development of Herceptin®.

Dr. Reinhardt has extensive experience in translational development as well as in early and late-stage clinical trial design. Under his leadership multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe. Amongst those were Blincyto® in acute lymphoblastic leukemia (ALL), Removab® in solid tumors as well as various sBLA/MAA for Herceptin® in adjuvant breast cancer and gastric cancer.

Prior to joining the pharma and biotech industry, Dr. Reinhardt held various academic medical positions and worked at the University of Tuebingen and Max Planck Institute, Munich to complete his curriculum in Neurology. Carsten Reinhardt received a Medical Degree in 1993 from the University of Munich, Germany and, in addition, completed a Ph.D. thesis in Cellular Immunology (summa cum laude).

He has co-authored more than 40 publications in peer-reviewed journals including Nature, Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine. He is an active member of ASCO, ASH, SITC as well as of ESMO, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel.

Further to his role at Immatics, Dr. Reinhardt is a non-executive director on the boards of Revitope Inc. (Boston, MA) and Theolytics (Oxford, U.K.).